Scarica l'app Stockscreener
1,108.09
4.14%
44.05
Pre-mercato:
1107.73
-0.36
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,064.04
Aprire:
$1077
Volume 24 ore:
4.65M
Relative Volume:
1.34
Capitalizzazione di mercato:
$991.76B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
54.80
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
+3.11%
1M Prestazione:
+9.68%
6M Prestazione:
+43.37%
1 anno Prestazione:
+43.30%
Intervallo 1D:
$1,075.96
$1,117.66
Intervallo di 1 settimana:
$1,033.38
$1,117.66
Portata 52W:
$623.78
$1,117.66
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Dow Drops, Eli Lilly Rockets — And Google Quietly Beats Apple at Its Own Game - Eudaimonia and Co
Eli Lilly completes billion-dollar acquisition of US biotech company - medwatch.com
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com UK
Eli Lilly Shares Surge on Strategic Expansion in Metabolic Therapeutics - AD HOC NEWS
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Lilly inks $950M deal to develop bi- and tri-specifics with InduPro - FirstWord
Ventyx Biosciences Upon Termination Of Merger Under Specified Circumstances, Co Will Be Required To Pay Eli Lilly Termination Fee Of $44 Million - TradingView — Track All Markets
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy - Reuters
Eli Lilly & Co (LLY) Receives a New Rating from Jefferies - The Globe and Mail
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus - TechStock²
Eli Lilly (LLY) Set to Acquire Ventyx Biosciences in Cash Deal - GuruFocus
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - PR Newswire
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecif - PharmiWeb.com
Eli Lilly Joins Trump Program Expanding Obesity Drug Access - Bloomberg Law News
Eli Lilly (LLY) Partners with InduPro for Oncology Innovations - GuruFocus
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Stocktwits
InduPro, Inc. Announces Strategic Collaboration with Eli Lilly and Company to Develop First-In-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro?s Proximity-Guided Platform - MarketScreener
Lilly to work with InduPro on developing oncology therapies in up to $950M deal - Seeking Alpha
Eli Lilly and Regencell among market cap stock movers on Wednesday - Investing.com
Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly - Investing.com
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition - Benzinga
Lilly in talks to buy Ventyx Biosciences for more than $1B, WSJ reports - Indianapolis Business Journal
Aktis Oncology secures Lilly as anchor investor for upsized US IPO - Reuters
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Finviz
The Truth About Eli Lilly and Co: Is Wall Street’s Favorite Drug Stock Still Worth the Hype? - AD HOC NEWS
Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup - TipRanks
Eli Lilly’s Billion-Dollar Push to Lead the Obesity Drug Market - AD HOC NEWS
Eli Lilly surges ahead on raised price target - medwatch.com
Eli Lilly (LLY) Nears $1 Billion Acquisition of Ventyx Biosciences (VTYX) - GuruFocus
Eli Lilly and Intel lead market cap stock movers on Wednesday - Investing.com
Eli Lilly Set to Back Aktis Oncology’s Upsized $318 Million IPO - Bloomberg.com
Eli Lilly stock hits all-time high of 1113.03 USD By Investing.com - Investing.com South Africa
Eli Lilly stock hits all-time high of 1113.03 USD - Investing.com
Why Did Eli Lilly (LLY) Shares Surge Today? Key Factors - Tokenist
Companies are discussing a deal in which Eli Lilly would pay $14 a share in cash for Ventyx- WSJ - MarketScreener
Exclusive | Eli Lilly Nears Deal for Biotech VentyxWSJ - The Wall Street Journal
Stock Market Today: Dow Futures Up, S&P 500 And Nasdaq Slip As ADP Jobs Data Signals Modest Rebound— Mobileye, Penguin Solutions In Focus (UPDATED) - Benzinga
Eli Lilly (LLY) Receives a Price Target Boost from UBS Analyst | - GuruFocus
Ventyx Biosciences said to be in takeover talks with Eli Lilly, shares surge - Sharecast.com
Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Aktis Oncology seeks $945 million valuation, secures Lilly as IPO anchor investor - marketscreener.com
BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab - Business Wire
Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billi - GuruFocus
Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion - Yahoo Finance
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus - Pharmaceutical Technology
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus - BioSpace
Eli Lilly Is Closing In on Deal With Biotech Ventyx, WSJ Says - Bloomberg.com
Eli Lilly Stock (LLY) Target Raised To $1,250 As Analysts Grow Increasingly Bullish - AskTraders.com
Ventyx Biosciences (VTYX) Stock: Eli Lilly Acquisition Talks Send Shares Soaring 62% - CoinCentral
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.32%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):